The Pharmacy Guild of Australia, a powerful lobby group, is accused of wielding undue influence over the Australian healthcare system, particularly in the pharmaceutical sector. This influence, according to the Grattan Institute, is at the expense of patients and taxpayers, who are missing out on cheaper medicines and more transparent negotiations.
The Power of the Pharmacy Guild
The Pharmacy Guild, representing most pharmacy owners, is a major political player in the health industry. It secures almost $4 billion annually in taxpayer funding through negotiations with the government, which take place behind closed doors with minimal transparency. This lack of transparency is a cause for concern, as it suggests that the interests of the guild, rather than the patients, may be prioritized.
Profits and Patients
The guild's influence is further highlighted by the significant profits of its members. Peter Breadon, Grattan's health director, notes that pharmacy profits have more than doubled in the last decade. This raises questions about the balance between profit and patient care, especially when the guild's negotiations result in generous terms that protect pharmacy owners from revenue declines.
Dispensing Fees and Patient Charges
One of the key issues is the dispensing fee, which is not based on the actual cost of dispensing. This fee, about $9 for an average medicine, is a significant source of revenue for pharmacies. The report suggests that the guild has blocked efforts to establish the real cost of dispensing, allowing the government to negotiate fees in the dark. This lack of transparency could be leading to taxpayers paying more than necessary.
Additionally, patients are charged the 'allowable additional patient charge' of $2.80 on some medicines, which the report deems unjustified. The $1 discount on medicines, which saved patients $48 million in 2022-23, is also set to end by 2029, further impacting patients' wallets.
Location Rules and Competition
The Pharmacy Guild has also imposed restrictions on the establishment of new pharmacies, requiring them to be at least 10 kilometers from existing ones. While the guild argues that this ensures vulnerable communities are not left without services, Grattan suggests that it stifles competition and benefits existing pharmacies at the expense of patients. The report recommends scrapping these location rules, citing examples from other countries where such rules have been abolished, leading to more pharmacies, longer opening hours, and lower prices.
Recommendations and Future Steps
The Grattan report calls for a radical change in the funding model, suggesting the abolition of Community Pharmacy Agreements by 2029. If this doesn't happen, the report recommends involving pharmacists and patients in negotiations and allowing the Independent Health and Aged Care Pricing Authority to set funding rates. However, the Health Minister, Mark Butler, has not committed to these recommendations, indicating a potential challenge in implementing such changes.
In conclusion, the Grattan Institute's report highlights a complex issue of power dynamics and transparency in the Australian healthcare system. The Pharmacy Guild's influence, while potentially beneficial to the industry, may be hindering patient access to affordable medicines and transparency in funding negotiations. As the debate continues, the future of pharmaceutical pricing and patient care in Australia hangs in the balance.
